Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated February 18, 2022, reports on a capital raising event by Calyxt, Inc., a majority-owned subsidiary (61.8% as of December 31, 2021) of Cellectis S.A. The filing details an underwritten offering of common stock and warrants by Calyxt to an institutional investor.
Key Financial Metrics
The filing provides preliminary, unaudited financial estimates for Calyxt, Inc. as of December 31, 2021. Cellectis S.A. consolidated financial metrics are not provided in this document.
- Cash and Cash Equivalents (Calyxt): $13.7 million
- Restricted Cash (Calyxt): $0.6 million
- Total Current Liabilities (Calyxt): $4.1 million
- Financing Lease Obligations (Calyxt): $17.9 million (including current portion)
- Offering Price: $1.41 per share (combined stock/pre-funded warrant and common warrant)
Revenue, profit, cash flow, and margin data are not provided in this filing.
Material Changes and Offering Details
Calyxt announced the placement of the following securities:
- 3,880,000 shares of common stock.
- Pre-funded warrants to purchase up to 3,880,000 shares (exercise price: $0.0001; immediately exercisable).
- Common warrants to purchase up to 7,760,000 shares (exercise price: $1.41; exercisable six months after issuance; five-year term).
Each share or pre-funded warrant was sold with one accompanying common warrant. The filing also notes updated business and risk factor disclosures for Calyxt attached as exhibits.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding Calyxt's business and the offering. Management notes that the preliminary financial information is subject to adjustment upon completion of year-end closing procedures and audit by an independent registered public accounting firm. Material adjustments could occur. The filing includes updated risk factor disclosures specific to Calyxt, Inc.
Investor Verification Checklist
- Verify the final audited financial statements for Calyxt, Inc. as of December 31, 2021, to confirm the preliminary cash and liability figures.
- Review the "Updated Calyxt Business Disclosure" (Exhibit 99.1) and "Updated Calyxt Risk Factor Disclosure" (Exhibit 99.2) for specific operational risks.
- Confirm the total capital raised from the offering and the impact on Cellectis S.A.'s consolidated balance sheet.
- Monitor for any material adjustments to the preliminary financial estimates mentioned in the filing.